chronic renal failure
Conditions
Interventions
Use MFX-30Ueco in the first week, and MFX-30UWeco in the second and third weeks. Blood will be collected before and after the first HDF in the 1st and 3rd week. During the first HDF in the 1st and 3rd
Sponsors
Yamagishi Nephrology Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who have undergone online HDF for more than 1 month before obtaining consent 2) Patients who can stably maintain a blood flow rate of 250mL/min 3) Patients using a hemodiafilter with a membrane area of 3.0 m2 or more 4) Patients whose dialysis time is 4 hours or more 5)Patients who are ambulatory 6)Patients who have given written consent to participate in this study
Exclusion criteria
Exclusion criteria: 1) Patients who need to use other blood purification therapies such as peritoneal dialysis that may affect the evaluation of research equipment during research participation. 2)Patients with a past history of acute symptoms such as anaphylactic reactions due to polyethersulfone membrane or polyvinylpyrrolidone (PVP) 3) Patients participating in other clinical studies that may affect the results of this study while participating in the study 4) Those with renal failure due to a serious disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Removal rate and amount of urea, creatinine, inorganic phosphorus, beta2MG, alpha1MG, albumin, measured at the start of the study and 1 week after changing the hemodiafilter | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of change in White Blood Cell count and Platelet count before and after dialysis, measured at the start of the study and 1 week after changing the hemodiafilter Transmembrane pressure difference (TMP) and pressure drop during dialysis, measured at the start of the study and 1 week after changing the hemodiafilter | — |
Countries
Japan
Contacts
Public ContactTakashi Yamagishi
Yamagishi Nephrology Clinic Artificial dialysis department
Outcome results
None listed